April 1-3, 2025 | Boston, MA
www.tcr-therapies-summit.com

SAVE $100 WHEN YOU REGISTER BY TUESDAY, APRIL 1

6th Annual

TCR-based Therapies Summit

Advancing TCR-based Cell Therapies & Bispecific Approaches

Validate Novel Targets, Uncover Effective Biomarkers & Enhance TCR Discovery & Optimization to Expand Patient Population & Achieve Clinical Validation

Expert Speakers Include:

Annelise Vuidepot
Chief Technology Officer
Immunocore

Andrea Moyer-Mokler
Vice President & Global Head, Clinical Science
Immatics

Dora Hammerl
Co-Founder & Vice President, Research & Development
Pan Cancer T

Elliot Norry
Chief Medical Officer
Adaptimmune

Cassian Yee
Founder
Mongoose Bio

Barbara Sennino
Senior Vice President, Early Development
3T Biosciences

Proud to Partner With:

ADIMAB · Alithea bio · Alloy Therapeutics · BioMed X · BioCentriq · BPS Bioscience · Miltenyi Biotec · Promega

+1 617 455 4188 info@hansonwade.com
www.tcr-therapies-summit.com Cell Immunotherapy

hansonwade

Transforming T-Cell Receptor Cell & Biologic Approaches

6th Annual TCR-based Therapies Summit
April 1-3, 2025 | Boston, MA

What a year for TCR-based therapies! **Adaptimmune** took the spotlight in August when they secured the first commercial approval for an engineered cell therapy in solid tumors with their TCR-T, Tecelra. Swiftly followed by positive clinical readouts and trials initiated by **Immatics, Triumvira, CDR-Life** and **Affini-T** alongside significant investments and partnerships worth of over $700M for **Galapagos, Adaptimmune, Enara Bio, Yellowstone Biosciences** and **Pan Cancer T**, all eyes are on the TCR community in 2025.

The **6th TCR-based Therapies Summit** returns as your only platform designed solely for TCR experts to unite and dive deep into T-cell receptor biology to conquer technical challenges from tumor-specific antigen discovery to optimized TCR design to cross-reactivity prevention, so you can transform your pipeline of cell, bispecific, antibody, or TCR mimic therapies.

As the field continues to gain clinical momentum, hear exclusive clinical insights from **Adaptimmune, Immatics, TScan, CDR-Life** and **Obsidian Therapeutics** to uncover underlying TCR biology, enhance biomarker selection, expand TCR repertoire, amplify solid tumor durability and boost target discovery beyond MAGE-A4, NY-ESO-1, PRAME and KRAS to allow delivery of therapies to the entire patient population.

New for 2025, explore TCR applications beyond oncology, in autoimmune and viral indications, and discover how you can harness cross-learnings to propel therapy development.

Join peers across ***Discovery, R&D, Translation*** and ***Clinical Development*** at this unique learning experience and close-knit networking platform, created solely for the TCR community. Gain an exclusive industry overview and turbocharge your technical expertise to bring best-in-class TCR-based therapies to the wider population.

What our speakers have to say:

"The TCR-based Therapies Summit is the leading conference to gather all US and European industry stakeholders that are advancing the next generation of TCR-based cell therapies and biologics"

Felix Lorenz, Chief Executive & Scientific Officer, **Captain T Cell, *2025 Expert Speaker***

"The summit offers an unparalleled opportunity to connect with top researchers and biotech experts, fostering critical discussions that shape the future of our field"

Roberto Chiarle, Founder, **ALKemist Bio, *2025 Expert Speaker***

KEY BENEFITS OF ATTENDING

Discover novel antigens and **validate tumor-specificity** and targeting potential to **diversify target repertoire** while **minimizing off-target effects with Pan Cancer T** and **ALKemist Bio**

Demonstrate TCR therapy safety and **efficacy** in patients to **secure clinical validation** and prove their therapeutic potential of cell and bispecific approaches with **Adaptimmune, Immunocore, Immatics** and **Obsidian Therapeutics**

Turbocharge discovery of effective TCR molecules and **boost potency** and **specificity** through affinity maturation and engineering while **preventing cross-reactivity with BioNTech, 3T Biosciences** and **TScan Therapeutics**



Uncover robust biomarkers to distinguish responsive patient populations **and track TCRs *in vivo*** to support immune monitoring and mechanism of action with **Marengo Therapeutics**

Transform durability and **infiltration** in the solid tumor microenvironment through **engineering, bispecific design** and **synthetic biology** to **boost anti-tumor with Moonlight Bio, T-Knife Therapeutics, Captain T Cell** and **Obsidan Therapeutics**

Your Expert Speakers

Barbara Sennino
Senior Vice President, Early Development
3T Biosciences

Elliot Norry
Chief Medical Officer
Adaptimmune

Lauren Stopfer
Executive Director, Proteomics & Innovation
Aethon Therapeutics

Garrett Rappazzo
Senior Scientist
Adimab

Dongxing Zha
Chief Executive Officer, Keyway TCR Discovery
Alloy Therapeutics

Roberto Chiarle
Scientific Founder
Alkemist Bio

Luke Pase
Chief Technology Officer
Anocca

Claudia Ouyang
Senior Director, Cell & Gene Therapies
BioNTech

John Linder
Head of Immunology Discovery & Research, US
BioMed X

Joe Akin
Executive Director, Business Development
BlueSphere Bio

Felix Lorenz
Chief Executive & Scientific Officer
Captain T Cell

Stephanie Jungmichel
Pharmacology Leader
CDR-Life

Rachel Woolley
Principal Scientist, Protein Engineering
Etcembly

Gene Uenishi
Associate Director, Technology
GentiBio

Andrea Mayer-Mokler
Vice President Global Head, Clinical Science
Immatics

Annelise Vuidepot
Chief Technology Officer
Immunocore

Zhen Su
Chief Executive Officer
Marengo Therapeutics

Cassian Yee
Founder
Mongoose Bio

Mandy Iniguez
Vice President, Research & Development
Moonlight Bio

Parameswaran Hari
Chief Development Officer
Obsidian Therapeutics

Michelle Ols
Vice President, Head of Cell Therapy Research
Obsidian Therapeutics

Dora Hammerl
Co-Founder & Vice President, Research & Development
Pan Cancer T

Lilly Wollman
Co-Founder & Chief Executive Officer
Synteny

Petra Mlcochova
Project Leader
T-Therapeutics

Marleen van Loenen
Executive Director, Next-Generation Technologies
T-Knife Therapeutics

Cagan Gurer
Senior Vice President, Discovery & Preclinical Development
TScan Therapeutics

Pre-Conference Workshop Day
Tuesday, April 1

Workshop Check-In & Coffee Networking — 8.00

Workshop A — 9.00-12.00

Spearheading Discovery & Validation of Novel Targets to Expand Indication & Treatment Potential

TCR-based therapies open a huge pool of intracellular target antigens that cannot be targeted by other therapeutics, but currently success has only been seen in a small portion of this target repertoire. Therefore, it is imperative to diversify the range of effective targets, as well as to validate their tumor-specificity to mitigate against off-target effects in healthy tissues. Join this deep dive session to hear case studies on novel target development and collaborate to further efforts to expand the range of effective targets.

This workshop will gather experts to discuss:

- Advancing methods such as mass spectrometry to screen tumor samples and identifying novel antigens which are tumor-specific
- Discussing novel areas with potential for novel targets such as neoantigens and dark genome
- Leveraging bioinformatics and screens to validate tumor-specificity and frequency
- Predicting target peptide prevalence in patients and indications to determine viability for development

Workshop Leaders

Roberto Chiarle
Scientific Founder
ALKemist Bio

Dora Hammer
Co-Founder & Vice President, Research & Development
Pan Cancer T

Lunch Break & Networking — 12.00

Workshop B — 1.00 - 4.00

Transforming T-Cell Receptor Engineering & Affinity Maturation to Enhance Specificity & Efficacy While Guaranteeing Safety

TCR molecules are now being engineered and optimized to increase their efficacy through affinity maturation and modifications. However, it is vital to strike the perfect balance between affinity and specificity to ensure maximum efficacy with minimal cross reactivity. Discuss the benefits of modified TCRs compared to natural molecules, and best practice to safely improve TCR efficacy.

This workshop will gather experts to discuss:

- Engineering T-cell receptors to increase their specificity and decrease the chance of cross-reactivity and off-target effects
- Boosting TCR efficacy by leveraging affinity maturation while maintaining specificity minimizing off-target toxicity
- Considering the benefits and challenges of engineered TCRs compared to natural TCRs to determine best method for your therapeutic
- Reviewing and balancing the need for TCR optimization for both cell and biologic approaches to equip each modality with optimal TCRs

Workshop Leaders

Rachel Woolley
Principal Scientist, Protein Engineering
Etcembly

Joe Akin
Executive Director, Business Development
BlueSphere Bio

End of Pre-Conference Workshop Day — 4.00

Conference Day One
Wednesday, April 2

7.30 Check-In & Coffee Networking

8.25 Chair's Opening Remarks

Validating the Safety & Efficacy of TCR-Based Therapies in the Clinic

8.30 **ACTengine IMA203 & IMA203CD8 TCR-T Cell Therapy Targeting PRAME in Solid Tumor Patients**

Andrea Mayer-Mokler
Vice President Global Head of Clinical Sciences
Immatics

- Phase 1b clinical data on IMA203 demonstrate deep and durable responses in heavily pretreated metastatic melanoma patients at RP2D
- Next-generation IMA203CD8 Phase 1a dose escalation data show enhanced pharmacology and potency per cell; to be evaluated for future in development in solid cancers with medium-level PRAME copy numbers
- SUPRAME, randomized-controlled Phase 3 trial to evaluate IMA203 in 2L+ metastatic melanoma patients, initiated in December 2024

9.00 **T-Cell Therapies in the Real World**

Elliot Norry
Chief Medical Officer
Adaptimmune

- Data supporting FDA approval of afamitresgene autoleucel, the first engineered T-cell therapy for solid tumors, targeting unresectable or metastatic synovial sarcoma
- Optimizing the regulatory process throughout development, and paving the way for future cell therapies
- Data from the IGNYTE ESO trial with letetresgene autoleucel for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS)

9.30 **Next Generation TIL: OBX-115 Engineered TIL Cell Therapy with Regulatable mbIL15**

Parameswaran Hari
Chief Development Officer
Obsidian Therapeutics

- OBX-115 is an engineered TIL cell therapy that leverages regulatable membrane-bound IL15 (mbIL15) to improve the expansion, persistence, safety, and efficacy of TIL cell therapy for patients with solid tumors
- Unlike IL2, mbIL15 promotes a predominant CD8+, memory, and "stem-like" progenitor phenotype, and does not increase immunosuppressive regulatory T-cells
- Clinically, we have observed a safety profile that is positively differentiated from non-engineered TIL cell therapy, which requires high-dose systemic IL2, as well as promising early efficacy and translational correlates

10.00 **Panel Discussion: Evaluating the Cell vs Bispecific Evolution to Elevate Their Respective Advantages**

- Consolidating the clinical advances for both approaches while highlighting the next generation for each method
- Comparing clinical efficacy and safety data to highlight benefits and challenges of each modality
- Discussing how the impact of various targets and TCR enhancements may differ for each approach to determine priorities for future modification
- Reflecting on where each modality thrives and how they can learn from each other to further advance the TCR-based therapy field

Marleen van Loenen
Executive Director, Next-Generation Technologies
T-Knife Therapeutics

Barbara Sennino
Senior Vice President, Early Development
3T Biosciences

Petra Mlcochova
Project Leader
T-Therapeutics

10.45 Morning Refreshment Break & Speed Networking

Approaching Effective TCR Discovery & Optimization to Mediate Safe & Effective Targeting

11.35 **Showcasing a Cellular TCR Evolution Platform to Upscale TCRs for Clinical Deployment**

Luke Pase
Chief Technology Officer
Anocca

NEW DATA

- A novel platform to generate clinically actionable TCRs beyond the native TCR repertoire
- Utilizing synthetic biology to diversify TCR frameworks and functionally select variants in T-cell libraries
- Validating optimized TCR for allo-reactivity and cross-reactivity to demonstrate safety

Conference Day One
Wednesday, April 2

12.05 **Developing a Robust, Antigen-Agnostic In Silico Prediction Model to Select & Test Personalized TCRs (pTCRs) for Tumor-Reactivity**

Claudia Ouyang
Senior Director, Cell & Gene Therapies
BioNTech

NEW DATA

- Predicting tumor-reactive pTCRs via gene signature to enable target diversity and rapid TCR discovery
- Generating wet-lab TCR validation data in a high-throughput format to train prediction model
- Validating selected pTCRs using patient-derived tumor organoids to inform preclinical efficacy

12.35 **Breaking Down Solid Tumor Barriers with a Novel Bispecific T-Cell Engager Against a Novel pHLA Target**

Barbara Sennino
Senior Vice President, Early Development
3T Biosciences

- Leveraging the 3T-TRACE platform to screen TCR and TCR mimetic molecules for specific and off-target cross-reactivities
- Building highly specific and safe TCRs for shared targets to effectively treat solid tumors

1.05 **Self-Validating Tools for Functional Pan-HLA Epitope & TCR Discovery**

John Linder
Head of Immunology Discovery & Research, US
BioMed X

- Data from our lab demonstrating the need for wet-lab validation/discovery methodologies that do not rely on predictive tools or unproven input
- T-FINDER (T-cell functional identification and (Neo-)antigen discovery of epitopes and receptors) is a modular, plug-and-play system for high-throughput interrogation of putative TCR:ligand interactions for both class I and class II HLA-presented epitopes
- ESTEL (Epitope-specific T-cell expansion on libraries) is an HLA-agnostic tool for identifying TCRs of interest on a set of putative ligands

1.15 **Lunch Break and Networking** | **Private Lunch with Miltenyi** Miltenyi Biotec

Reflecting on the Year & Turbocharging Future Success of the TCR Field

2.15 **Industry Leaders' Fireside Chat: A Commercial TCR-T & TCR Bispecific – What's Next?**

- Reflecting on the past: celebrating the first TCR-T commercial approval and its impact on the field, along with novel clinical data
- Determining the current state of play: discussing what challenges remain, the current funding environment and the priority for the field to outline present focus
- What's next? Discussing the potential for allogeneic or *in vivo* approaches, scalable manufacturing and expansion to novel patient populations

Andrea Mayer-Mokler
Vice President & Global Head of Clinical Sciences
Immatics

Annelise Vuidepot
Chief Technology Officer
Immunocore

Zhen Su
Chief Executive Officer
Marengo Therapeutics

Elliot Norry
Chief Medical Officer
Adaptimmune

Delivering to More Patient Populations by Expanding HLA Coverage

3.00 **Selection of High Affinity T-Cell Receptors from Large Fully Human Pre-Immune Yeast Libraries**

Garrett Rappazzo
Senior Scientist
Adimab

- Soluble TCRs can co-opt peptide-HLA (pHLA) recognition to eradicate virally infected and cancerous cells but require high affinity for efficacy in clinically validated T-cell engager formats
- Native TCR repertoires are pruned by central tolerance, limiting the discovery of high-affinity TCRs against many therapeutic pHLA targets and posing a significant barrier to the development of soluble TCR-based therapeutics
- Designing and selecting the first fully human pre-immune TCR libraries built in yeast, facilitating the rapid and high-throughput discovery of diverse high affinity TCRs that retain target pHLA specificity, providing new opportunities for potent and specific therapeutics

3.30 **Afternoon Break & Poster Session**

Conference Day One
Wednesday, April 2

Cagan Gurer
Senior Vice President, Discovery & Preclinical Development
TScan Therapeutics

NEW DATA

4.00 **Targeting Novel Epitopes & HLA Molecules to Expand Patient Populations**

- Utilizing innovative platforms and mass spectrometry to find novel epitopes presented by frequent HLAs
- Validating the best TCR-HLA target combinations for clinical success
- Choosing the right HLAs to expand coverage to minority patient populations

Dongxing Zha
Chief Executive Officer, Keyway TCR Discovery
Alloy Therapeutics

4.30 **Next-Generation TCRm TCE Therapeutics: A Paradigm Shift in Solid Tumor Immunotherapy**

- TCRm targeting of undruggable intracellular proteins presents a unique opportunity for immunotherapy.
- T cell engagers (TCEs) are emerging as effective therapies for solid tumors.
- The Keyway TCRm Discovery platform provides an end-to-end workflow, delivering next-generation immunotherapies from target identification to clinical application

Lauren Stopfer
Executive Director, Proteomics & Innovation
Aethon Therapeutics

NEW DATA

5.00 **Cross-HLA Targeting of Synthetic Neoepitopes with T-Cell Engagers to Eradicate KRASG12C Inhibitor-Resistant Cancers**

- Development of high-specificity and high-affinity T-cell engaging bispecific antibodies (HapImmune antibodies) targeting KRASG12C inhibitor-modified HLA peptides (hapten-peptides, “p*MHCs”)
- Direct detection of p*MHCs by mass spectrometry, detailed target characterization, and demonstrated in vitro/in vivo activity of HapImmune antibodies
- Demonstration of the molecular-basis for cross-HLA recognition, examples spanning alleles within and across HLA supertypes

Boosting Biomarker & Companion Diagnostics for TCR Therapies to Optimize Patient Selection & Accelerate Clinical Success

Zhen Su
Chief Executive Officer
Marengo Therapeutics

NEW DATA

5.30 **Leveraging Companion Diagnostics (CDx) to Distinguish Target Patient Populations**

- Setting up your CDx tools early and evolving your CDx tools to cater to advancing clinical trials
- Understanding guidelines and retaining flexibility to adjust for changing diagnostics regulations
- Leveraging CDx to accelerate patient recruitment

6.00 **Close of Conference Day One**

Conference Day Two
Thursday, April 3

8.00 Check-In & Coffee Networking

8.55 Chair's Opening Remarks

Pioneering TCR Applications Beyond Oncology to Expand Treatment Potential

Gene Uenishi
Associate Director, Technology
GentiBio

9.00 **Expanding TCR Therapy Success by Pursuing Autoimmune Treatments**

- Taking learnings in TCR efficacy and safety from oncology and applying to optimize
- Evaluating your approach characteristics to determine the most suitable target indication
- Balancing durability and safety in non-oncology patient populations

Annelise Vuidepot
Chief Technology Officer
Immunocore

9.30 **Harnessing TCR Bispecifics to Tackle Autoimmune Diseases** NEW DATA

- Adapting the ImmTAX platform to address autoimmune diseases
- First clinical programme for the treatment of Type I diabetes

Unlocking the Next-Generation of TCR-Based Therapies

Lilly Wollman
Co-Founder & Chief Executive Officer
Synteny

10.00 **Pioneering Artificial Intelligence & Machine Learning to Turbocharge TCR Therapy Development** NEW DATA

- Developing AI to rapidly screen TCR molecules to predict target binding
- Accelerating screening of TCR libraries to identify effective TCR molecules with minimal off-target effects
- Utilizing AI to influence the design for optimal synthetic TCR molecules

10.30 Morning Refreshment Break & Networking

Improving Efficacy to Reinvent Durability & Persistence in the Solid Tumor Microenvironment

11.30 **Panel Discussion: Reviewing Engineering Methods Potentiate Infiltration & Durability in the Hostile Microenvironment**

- Discussing engineering methods to alter T-cell or bispecific properties to increase trafficking to tumor site and enable prolonged killing
- Inhibiting immune suppression pathways to improve cell survival
- Considering implications of multi-engineering on cell viability and patient safety to mitigate adverse effects

Michelle Ols
Vice President, Head of Cell Therapy Research
Obsidian Therapeutics

Cassian Yee
Founder
Mongoose Bio

Mandy Iniguez
Vice President, Research & Development
Moonlight Bio

Dora Hammerl
Co-Founder & Vice President, Research & Development
Pan Cancer T

Conference Day Two
Thursday, April 3

Felix Lorenz
Chief Executive & Scientific Officer
Captain T Cell

12.30 **Using a Novel TGF-beta Switch to Prevent Exhaustion of T-Cells in the Solid TME**

- Introduction of a novel TGF-beta Switch Receptor: explaining how the novel switch modulates TGF-beta signalling to enhance T-cell functionality within the hostile solid tumor microenvironment (TME)
- Preventing T-cell exhaustion: demonstrating how this approach effectively prevents T-cell exhaustion, enabling repeated killing
- Implications for advanced Immunotherapies: discussing the integration of this technology into the toolbox of technologies of Captain T Cell to develop more effective treatments for solid tumors

1.00 **Lunch Break & Networking**

Marleen van Loenen
Executive Director, Next-Generation Technologies
T-Knife Therapeutics

NEW DATA

2.00 **Integrating a Co-Stimulatory CD8 Co-Receptor & a Tailored Switch Receptor to Boost Persistence and Anti-Tumor Activity**

- Identifying inhibitory factors in the tumor microenvironment by large scale tumor screening and translating these into activating signals through switch receptors
- Leveraging inhibitory switch receptors to boost engraftment during TCR-T cell trafficking
- Equipping cells with a costimulatory CD8 co-receptor to overcome lack of co-stimulatory signaling in the tumor

Transforming Clinical Strategy to Efficiently Progress the Next Wave of Therapies

2.30 **Round Table: Reflecting on Current Clinical Strategy to Enable Smooth Trial Recruitment & Progression**

- Evaluating best practice to select a target indication based on therapeutic approach
- Discussing challenges in patient screening and engagement to facilitate recruitment in early- and late-stage trials
- Sharing regulatory experiences to distinguish a clear path into and through the clinic
- Discussing manufacturability and scalability to cater to the growing patient population

Stephanie Jungmichel
Pharmacology Leader
CDR-Life

NEW DATA

3.30 **Strategies for Clinical Dose Selection of CDR404: a MAGE-A4/HLA-A2 Antibody-Based T-Cell Engager**

- Using Quantitative Systems Pharmacology (QSP) modeling for dose escalation and FIH study design for CDR404
- We discuss the key preclinical pharmacological data used for generation of a QSP model for CDR404
- Forward-looking perspectives and next generation antibody based TCEs targeting peptide-HLA on cancer cells

4.00 **Close of Conference Day Two**

> "This past year, the TCR field has been bolstered by product approvals, new company creation, and advances in primary and translational research. The 2025 TCR Summit will host expert researchers and drug developers covering the evolution of the field and addressing critical challenges on the road ahead"
>
> **Jordan Jarjour**, Chief Scientific Officer, **Moonlight Bio**

2025 Partners

Program Partner

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

www.adimab.com

Program Partner

Alloy Therapeutics accelerates the drug discovery process by providing access to best-in-class foundational drug discovery platforms, services, and company creation capabilities. Alloy Therapeutics has developed novel strains for fully human antibody discovery and created innovative technology to support a multitude of modalities that can help to quickly identify candidates. Leveraging our world class scientists, Alloy therapeutics platforms and services enables you to build a more robust antibody-based therapeutic pipeline.

www.alloytx.com

Hosting Partner

Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, transforming scientific discoveries into practical treatments for personalized medicine. With over 35 years of expertise, it supports biomedical discoveries and translates them into clinical applications, enhancing patient access to new therapies. Miltenyi Biotec focuses on offering integrated solutions for complex challenges in treating cancers, autoimmune diseases, and inherited disorders. Its Miltenyi Bioindustry division provides expert guidance to therapy developers efficiently from process development to commercialization. Headquartered in Bergisch Gladbach, it employs 4,900 people across 24 countries.

www.miltenyibiotec.com

Exhibition Partner

Alithea Biotechnology GmbH (GER) is providing cutting-edge HLA peptidomics technologies for target discovery, validation and off-target toxicity profiling since 2019. Alithea has a web-accessible quantitative HLA peptide database, HLA-Compass, allowing to navigate peptide presentation in health and cancer. Proprietary HLA peptide binding predictors and strong experience in the quantification of HLA ligands together with most sensitive timsToF Ultra-powered mass spectrometry equipment facilitate high quality and sensitivity. Proteogenomics capabilities and an in-house repository of HLA typed tissue samples facilitate rapid validation of hypotheses for TCR/TCRm drug discovery. Alithea happily supports you in solving RnD challenges from target discovery to IND submission.

www.alithea-bio.com

Exhibition Partner

BioCentriq is a highly versatile clinical-phase cell therapy contract development and manufacturing organization (CDMO). It has been successfully developing, manufacturing, and releasing GMP autologous and allogeneic cell therapies for clinical trials from 2022. BioCentriq is known for its high level of experience across the organization as a specialist CDMO. It specifically specializes in early and mid-stage cell therapies. BioCentriq is comprised of highly experienced and industry-recognized leadership, scientists, engineers, analysts, and manufacturing specialists. BioCentriq utilizes state-of-the-art quality systems, infrastructure, and digitalized processes. Its LEAP™ Advanced Therapy Platform has been designed to reduce manufacturing initiation timelines by over 50% from industry average. BioCentriq adds additional resources with the backing of Green Cross of South Korea, a global leader in the pharmaceutical and biotechnology sectors, as its majority shareholder, acquired for $73 million in May 2022.

www.biocentriq.com

2025 Partners

Exhibition Partner

BPS Bioscience strives to advance new scientific discoveries that lead to therapies by creating innovative research solutions. We drive advancements across a broad range of critical research areas, providing 4500+ recombinant cell lines, virus-based tools, proteins, biochemical and cell-based assay kits, and compound screening focused on drug discovery.

www.bpsbioscience.com

Exhibition Partner

Promega provides a broad portfolio of functional bioassays, immunoassays and protein characterization tools to accelerate your cell therapy drug discovery and development. We offer state-of-the-art reporter and health assays for potency testing, tools for TCR discovery and antigen specificity. All of our products are developed and manufactured under rigorous quality standards and our bioassays are pre-qualified according to ICH guidelines. Connect with us so we can help support your assay needs today!

www.promega.co.uk

Innovation Partner

BioMed X is an independent research institute with locations in Heidelberg, Germany, New Haven, and an open innovation incubator at Boehringer Ingelheim's R&D campus in Ridgefield, Connecticut, along with a global partner network. At the intersection of academia and industry, we drive pioneering research in oncology, immunology, neuroscience, platform technologies, and artificial intelligence. Supported by leading pharmaceutical companies, our projects are led by early-career scientists recruited from top institutions worldwide. Through global crowdsourcing and local incubation, we tackle major biomedical R&D challenges. With a focus on curiosity-driven exploration and rigorous validation, we advance translational biomedicine and foster cross-disciplinary innovation. Our research has also resulted in the development of new technologies for the pharmaceutical and biotech industries, such as T-Finder.

www.bio.mx/technologies/immunology-discovery/

> "The TCR-Based Therapies Summit uniquely delivers a broad overview of the field with the additional opportunity to dive deep with the experts driving the field. This meeting comes at an exciting and pivotal time for the field as more established therapies continue to mature and novel concepts are entering early clinical development"
>
> **Gary Shapiro**, Vice President, Discovery Biology, **Affini-T Therapeutics**

Partner With Us

6th Annual TCR-based Therapies Summit
April 1-3, 2025 | Boston, MA

Your Industry-Specific Platform to Build & Grow Relationships with the Spotlighted TCR Community

The **6th TCR-based Therapies Summit** returns in 2025 to capture the excitement among this specific community and wider industry. Bringing together a dedicated group of innovators pioneering best-in-class therapies, this unique forum continues to provide an unrivalled platform to connect and build relationships with these industry experts in an intimate environment promoting collaboration.

Now we have seen the commercial potential for TCR-based biologics and cell therapies alike, developers are hot on the trail to optimize and accelerate development from discovery through to commercialization, relying on robust partners and solutions across **TCR discovery, HLA typing, immune screening, preclinical models** and **companion diagnostics** to support them.

By partnering with the summit, you will leverage this preferred platform to showcase your capabilities to this exclusive audience.

Showcase your dedicated solutions and capabilities to an **engaged** and **tight-knit audience** of decision makers

Drive brand awareness and **differentiate from competitors** to place your company at the forefront of the industry

Meet and **build relationships** with **leading stakeholders** and educate experts on how you can support their TCR therapy development

Stay up to date with the **latest trends**, ensuring your commercial and development strategies match your clients

SENIORITY OF ATTENDEES*



- C-Suite – 18%
- VP/President/Head – 27%
- Director – 19%
- Scientist – 16%
- Other – 20%

TYPES OF COMPANIES ATTENDING*



- Drug Developer
- Equipment & Service Provider
- Research Institute
- Investor

*Audience breakdown from the 5th TCR-Based Therapies for Solid Tumors Summit

GET INVOLVED

Kieran Crewe
Commercial Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.tcr-therapies-summit.com/take-part/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

Dive into the **latest preclinical** and **clinical data** to **unlock treatment potential** and **distinguish TCR-based therapies** as **best-in-class treatments**

Discover strategic insights from across the TCR field to **build optimal therapeutics** and **streamline progression** through discovery, translation and clinical development

Connect and **collaborate** with industry peers at the only meeting focussed on the **intricacy of TCR biology** and celebrate a year of breakthroughs

Drug Developer Pricing*	Register by Tuesday, April 1	On The Door
Conference + Workshop Day	$4,097 **(Save $100)**	$4,197
Conference Only	$2,899 **(Save $100)**	$2,999

Academic & Not-For-Profit Pricing**	Register by Tuesday, April 1	On The Door
Conference + Workshop Day	$3,497 **(Save $100)**	$3,597
Conference Only	$2,499 **(Save $100)**	$2,599

Service & Solution Provider Pricing	Register by Tuesday, April 1	On The Door
Conference + Workshop Day	$4,997 **(Save $100)**	$5,097
Conference Only	$3,599 **(Save $100)**	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website forfull pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts**

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4 + Attendees**

**Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Revere Hotel Boston Common
200 Stuart St, Boston, MA 02116
https://www.reverehotel.com/